Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Sees Large Growth in Short Interest

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 10,189 shares, an increase of 67.9% from the May 14th total of 6,068 shares. Based on an average daily trading volume, of 7,808 shares, the short-interest ratio is currently 1.3 days. Approximately 0.0% of the shares of the stock are short sold.

Hedge Funds Weigh In On Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is owned by institutional investors and hedge funds.

Molecular Partners Stock Performance

MOLN stock traded down $0.28 during mid-day trading on Monday, reaching $3.84. 5,738 shares of the stock traded hands, compared to its average volume of 4,548. Molecular Partners has a one year low of $3.41 and a one year high of $5.36. The stock has a market capitalization of $154.84 million, a PE ratio of -1.98 and a beta of 1.07. The business has a 50-day moving average price of $4.11 and a two-hundred day moving average price of $4.31.

Molecular Partners (NASDAQ:MOLN) last released its earnings results on Monday, May 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). On average, equities analysts expect that Molecular Partners will post -1.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MOLN. TD Cowen reaffirmed a “buy” rating on shares of Molecular Partners in a report on Monday, March 16th. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Molecular Partners in a research note on Wednesday, April 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, April 10th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.